Hydroxyethyl starch and acute kidney injury in orthotopic liver transplantation: A single-center retrospective review

Anesthesia and Analgesia

Volumn 120, Issue 3, 2015, Pages 619-626

  Hand, William R ^a   Whiteley, Joseph R ^a   Epperson, Tom I ^a   Tam, Lauren ^b   Crego, Heather ^c   Wolf, Bethany ^a   Chavin, Kenneth D ^a   Taber, David J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIFIBRINOLYTIC AGENT; BILIRUBIN; CREATININE; FRESH FROZEN PLASMA; HETASTARCH; VASOACTIVE AGENT; ALBUMINOID; BIOLOGICAL MARKER; HETASTARCH DERIVATIVE; PLASMA SUBSTITUTE;

ACUTE KIDNEY FAILURE; ADULT; ASCITES; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE; COHORT ANALYSIS; COLLOID; CONTINUOUS HEMODIALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; ERYTHROCYTE; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRAOPERATIVE PERIOD; LENGTH OF STAY; LIVER FAILURE; LIVER TRANSPLANTATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OPERATIVE BLOOD LOSS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; THROMBOCYTE TRANSFUSION; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; AGED; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; FLUID THERAPY; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROCEDURES; PROPENSITY SCORE; RISK FACTOR; SOUTH CAROLINA; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; ADULT; AGED; ALBUMINS; BIOMARKERS; CREATININE; CROSS-SECTIONAL STUDIES; FEMALE; FLUID THERAPY; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; LINEAR MODELS; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PLASMA SUBSTITUTES; PROPENSITY SCORE; RETROSPECTIVE STUDIES; RISK FACTORS; SOUTH CAROLINA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84926331010     PISSN: 00032999     EISSN: 15267598     Source Type: Journal    
DOI: 10.1213/ANE.0000000000000374     Document Type: Review

References (26)

1. Barri YM, Sanchez EQ, Jennings LW, Melton LB, Hays S, Levy MF, Klintmalm GB. Acute kidney injury following liver transplantation: definition and outcome. Liver Transpl 2009;15:475-83
2. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31
3. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8.4:R204
4. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int 2008;73:538-46
5. O'Riordan A, Wong V, McQuillan R, McCormick PA, Hegarty JE, Watson AJ. Acute renal disease, as defined by the RIFLE criteria, post-liver transplantation. Am J Transplant 2007;7:168-76
6. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006;43:S121-31
7. Arroyo V, Jiménez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000;32:157-70
8. Davis CL, Gonwa TA, Wilkinson AH. Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I. Liver Transpl 2002;8:91-109
9. Lima EQ, Zanetta DM, Castro I, Massarollo PC, Mies S, Machado MM, Yu L. Risk factors for development of acute renal failure after liver transplantation. Ren Fail 2003;25:553-60
10. Paramesh AS, Roayaie S, Doan Y, Schwartz ME, Emre S, Fishbein T, Florman S, Gondolesi GE, Krieger N, Ames S, Bromberg JS, Akalin E. Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant 2004;18:94-9
11. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003;9:741-7
12. Ernest D, Belzberg AS, Dodek PM. Distribution of normal saline and 5% albumin infusions in septic patients. Crit Care Med 1999;27:46-50
13. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology 2005;41:1211-9
14. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Ginès P, Rodés J. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-9
15. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R; SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350:2247-56
16. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SA; CHEST Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012;367:1901-11
17. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, Madsen KR, Møller MH, Elkjær JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Søe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjældgaard AL, Fabritius ML, Mondrup F, Pott FC, Møller TP, Winkel P, Wetterslev J; 6S Trial Group; Scandinavian Critical Care Trials Group. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012;367:124-34
18. FDA: Boxed Warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some setting [press release]. 2013. Available at: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm358271.htm
19. Reinhart K, Takala J. Hydroxyethyl starches: what do we still know? Anesth Analg 2011;112:507-11
20. Shafer SL. Shadow of doubt. Anesth Analg 2011;112:498-500
21. Ausin PC. Assessing balance in measured baseline covariates when using many-to-one matching on the propensity score. Pharamcoepidemiol Drug Saf 2008;17:1218-25
22. Sekhon JS. Multivariate Propensity Score Matching Software with Automated Balance Optimization: The Matching Package for R. J Stat Soft 2011;42.7:1-52
23. R Core Development Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: http://www.R-project.org
24. Mukhtar A, Aboulfetouh F, Obayah G, Salah M, Emam M, Khater Y, Akram R, Hoballah A, Bahaa M, Elmeteini M, Hamza A. The safety of modern hydroxyethyl starch in living donor liver transplantation: a comparison with human albumin. Anesth Analg 2009;109:924-30
25. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K; German Competence Network Sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358: 125-39
26. Boussekey N, Darmon R, Langlois J, Alfandari S, Devos P, Meybeck A, Chiche A, Georges H, Leroy O. Resuscitation with low volume hydroxyethylstarch 130 kDa/0.4 is not associated with acute kidney injury. Crit Care 2010;14:R40